A clinical trial update dated August 7, 2026 reports a change in status for a study involving gonadorelin. The trial, titled "Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer," is registered under identifier NCT06305598.
The study is listed as Phase 1 and its current status is active, not recruiting. This means the trial is ongoing but is not currently enrolling new participants.
Gonadorelin is an approved compound and is referenced in connection with this androgen deprivation therapy research. No results, outcomes, or efficacy data have been reported as part of this update. The available information reflects only the trial's registered title, phase, and recruitment status as of the listed date.
Readers interested in metastatic castration resistant prostate cancer research can find further details through the official trial registry listing. For additional context on gonadorelin's approved uses and background, see the compound overview.